• 1
    Siddik ZH. Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 2003; 22: 726579.
  • 2
    Galanski M, Arion VB, Jakupec MA, Keppler BK. Recent developments in the field of tumor-inhibiting metal complexes. Curr Pharm Des 2003; 9: 207889.
  • 3
    Zhang CX, Lippard SJ. New metal complexes as potential therapeutics. Curr Opin Chem Biol 2003; 7: 4819.
  • 4
    Eastman A. The formation, isolation and characterization of DNA adducts produced by anticancer platinum complexes. Pharmacol Ther 1987; 34: 15566.
  • 5
    Hall MD, Hambley TW. Platinum(IV) antitumor compounds: their biorganic chemistry. Coord Chem Rev 2002; 232: 4967.
  • 6
    Kelland LR. An update on satraplatin: the first orally available platinum anticancer drug. Expert Opin Invest Drugs 2000; 9: 137382.
  • 7
    Djinovic VM, Bogdanovic GA, Novakovic S, Sabo TJ. Synthesis and crystal structure of trans-dichloro(1,3-propylenediamine-N,N′-diacetato)platinum(IV) monohydrate. J Coord Chem 2004; 57: 5359.
  • 8
    Kaludjerovic GN, Bogdanovic GA, Sabo TJ. Synthesis and crystal structure of trans-dichloro(ethylenediamine-N,N′-di-3-propionato)platinum(IV) monohydrate. J Coord Chem 2002; 55: 81722.
  • 9
    Sabo TJ, Kaludjerovic GN, Poleti D, Karanovic LJ, Boccarelli A, Cannito F, Natile G. Cytotoxicity of some platinum(IV) complexes with ethylenediamine-N,N′-di-3-propionato ligand. J Inorg Biochem, 2004; 98: 216873.
  • 10
    Sabo TJ, Kaludjerovic GN, Grguric-Sipka SR, Heinemann FW, Trifunovic SR. Complex compounds of platinum(IV) and O,O-dialkyl- ethylenediamine-N,N′-di-3-propanoate ligands: a structural evidence for geometry of hydrolytic product of some esters. Inorg Chem Comm 2004; 7: 2414.
  • 11
    Djinovic VM, Mancic L, Bogdanovic GA, Vulic P, del Rosario G, Sabo TJ, Milosevic O. Aerosol synthesis of pure and Pt-doped ZnO particles using nitrate and pdda-Pt(IV) complex solutions. J Mater Res 2004; 20; 10213.
  • 12
    Kaludjerovic GN, Djinovic VM, Juranic ZD, Stanojkovic TP, Sabo TJ. Activity of some platinum(II/IV) complexes with O,O-n-butyl- and O,O-n-pentyl-ethylenediamine-N,N′-di-3-propanoate and halogeno ligands against HeLa and K562 cell lines and human PBMC. J Inorg Biochem 2005; 99: 48896.
  • 13
    Boreham CJ, Broomhead JA, Fairlie DP. A platinum-195 and nitrogen-15 NMR study of the anticancer drug cis-diamminedichloroplatinum(II) and its hydrolysis and oligomerization products. Aust J Chem 1981; 34: 65964.
  • 14
    Flick DA, Gifford GE. Comparision of in vitro cell cytotoxic assays for tumor necrosis factor. J Immunol Methods 1984; 68: 16775.
  • 15
    Mosmann T. Rapid colorimetric assay for cellular growth and survival: application for proliferation and cytotoxicity assays. J Immunol Methods 1983; 65: 5563.
  • 16
    Badovinac V, Trajkovic V, Mostarica-Stojkovic M. Nitric oxide promotes growth and major histocompatibility complex-unrestricted cytotoxicity of interleukin-2-activated rat lymphocytes. Scand J Immunol 2000; 52: 6270.
  • 17
    Reno F, Falcieri E, Luchetti F, Burattini S, Papa S. Discrimination of apoptotic cells in flow cytometry using trypan blue and FDA. Eur J Histochem 1997; 41: 1156.
  • 18
    Barzanti F, Zoli W, Susino MD, Ricotti L, Tesei A, Papa S, Reno F, Amadori D. Simultaneous determination of apoptosis and surface antigen expression in tumor adherent cells. J Biol Regul Homeost Agents 2001; 15: 35965.
  • 19
    Darzynkiewicz Z, Bruno S, Del Bino G, Gorczyca W, Hotz MA, Lassota P, Traganos F. Features of apoptotic cells measured by flow cytometry. Cytometry 1992; 13: 795808.
  • 20
    Versteeg HH, Nijhuis E, Van Den Brink GR, Evertzen M, Pynaert GN, Van Deventer SJ, Coffer PJ, Peppelenbosch MP. A new phosphospecific cell-based ELISA for p42/p44 mitogen-activated protein kinase (MAPK), p38 MAPK, protein kinase B and cAMP-response-element-binding protein. Biochem J 2000; 3: 71722.
  • 21
    Yamane Y, Furuichi M, Song R, Vani NT, Mulcahy RT, Ishikawa T, Kuo MT. Expression of multidrug resistance protein/GS-X pump and g-glutamylcysteine synthetase genes is regulated by oxidative stress. J Biol Chem 1998; 273: 3107580.
  • 22
    Wang X, Martindale JL, Holbrook NJ. Requirement for ERK activation in cisplatin-induced apoptosis. J Biol Chem 2000; 275: 3943543.
  • 23
    Persons DL, Yazlovitskaya EM, Pelling JC. Effect of extracellular signal-regulated kinase on p53 accumulation in response to cisplatin. J Biol Chem 2000; 275: 3577885.
  • 24
    Woessmann W, Chen X, Borkhardt A. Ras-mediated activation of ERK by cisplatin induces cell death independently of p53 in osteosarcoma and neuroblastoma cell lines. Cancer Chemother Pharmacol 2002; 50: 397404.
  • 25
    Yeh PY, Chuang SE, Yeh KH, Song YC, Ea CK, Cheng AL. Increase of the resistance of human cervical carcinoma cells to cisplatin by inhibition of the MEK to ERK signaling pathway partly via enhancement of anticancer drug-induced NF-κB activation. Biochem Pharmacol 2002; 63: 142330.
  • 26
    Blagosklonny MV. Prospective strategies to enforce selectively cell death in cancer cells. Oncogene 2004; 23: 296775.
  • 27
    Ng CP, Bonavida B. A new challenge for successful immunotherapy by tumors that are resistant to apoptosis: two complementary signals to overcome cross-resistance. Adv Cancer Res 2002; 85: 14574.
  • 28
    Reiter I, Krammer G, Schwamberger G. Differential effect of apoptotic versus necrotic tumor cells on macrophage antitumor activity. J Immunol 1999; 163: 17302.
  • 29
    Galluci S, Lolkema M, Matzinger P. Natural adjuvants: endogenous activators of dendritic cells. Nat Med 1999; 5: 124955.
  • 30
    Sauter B, Albert ML, Francisco L, Larsson M, Somersan S, Bhardwaj N. Consequences of cell death: exposure to necrotic tumor cells, but not primary tissue cells or apoptotic cells, induces the maturation of immunostimulatory dendritic cells. J Exp Med 2000; 191: 42330.
  • 31
    Park SA, Park HJ, Lee BI, Ahn YH, Kim SU, Choi KS. Bcl-2 blocks cisplatin-induced apoptosis by suppression of ERK-mediated p53 accumulation in B104 cells. Brain Res Mol Brain Res 2001; 93: 1826.
  • 32
    Persons DL, Yazlovitskaya EM, Cui W, Pelling JC. Cisplatin-induced activation of mitogen-activated protein kinases in ovarian carcinoma cells: inhibition of extracellular signal-regulated kinase activity increases sensitivity to cisplatin. Clin Cancer Res 1999; 5: 100714.
  • 33
    Hayakawa J, Ohmichi M, Kurachi H, Ikegami H, Kimura A, Matsuoka T, Jikihara H, Mercola D, Murata Y. Inhibition of extracellular signal-regulated protein kinase or c-Jun N-terminal protein kinase cascade, differentially activated by cisplatin, sensitizes human ovarian cancer cell line. J Biol Chem 1999; 274: 3164854.
  • 34
    Cui W, Yazlovitskaya EM, Mayo MS, Pelling JC, Persons DL. Cisplatin-induced response of c-jun N-terminal kinase 1 and extracellular signal-regulated protein kinases 1 and 2 in a series of cisplatin-resistant ovarian carcinoma cell lines. Mol Carcinog 2000; 29: 21928.
  • 35
    Fiers W, Beyaert R, Declercq W, Vandenabeele P. More than one way to die: apoptosis, necrosis and reactive oxygen damage. Oncogene 1999; 18: 771930.
  • 36
    Senturker S, Tschirret-Guth R, Morrow J, Levine R, Shacter E. Induction of apoptosis by chemotherapeutic drugs without generation of reactive oxygen species. Arch Biochem Biophys 2002; 397: 26272.
  • 37
    Iwamato Y, Kawano TU, Ozumi J, Aoki K, Baba T. “Two-route chemotherapy” using high-dose ip cisplatin and iv sodium thiosulfate, its antidote, for peritoneally disseminated cancer in mice. Cancer Treat Rep 1984; 68: 136773.
  • 38
    Robbins KT, Stornolio AM, Kerber C, Vicario D, Seagren S, Shea M, Hanchett C, Los A, Howell SB. Phase I study of highly selective supradose cisplatin infusions for advanced head and neck cancer. J Clin Oncol 1994; 12: 211320.
  • 39
    Muldoon LL, Walker-Rosenfeld SL, Hale C, Purcell SE, Bennett LC, Neuwelt EA. Rescue from enhanced alkylator-induced cell death with low molecular weight sulfur-containing chemoprotectants. J Pharmacol Exp Therap 2001; 296: 797805.
  • 40
    Zafarullah M, Li WQ, Sylvester J, Ahmad M. Molecular mechanisms of N-acetylcysteine actions. Cell Mol Life Sci 2003; 60: 620.